media – Page 29 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Types, Triggers And New Treatments

SUNDAY, Sept. 14, 2025 (HealthDay News) — Everyone gets headaches, but not all headaches are the same. For some, they’re a quick inconvenience. For others, they can be intense, long-lasting and even disabling, disrupting daily life for days or weeks. Experts say finding the right treatment depends on identifying the type of headache and understanding what triggers it. “We define chronic headache as having more than 15 headache days per month. So, more days with headache than not,” Michael Oshinsky, a pain expert at the National Institutes of Health (NIH), told its monthly newsletter News In Health. The most common kind is a tension-type headache, often linked to stress, lack of sleep, dehydration or poor posture. Pain usually feels mild to moderate and affects both sides of the head. Migraines are another frequent cause of disabling pain. Unlike tension headaches, migraines are a complex brain condition that can cause: Severe ...
- Source: drugdu
- 150
- September 15, 2025
Dobutamine Hydrochloride Injection Passes Consistency Evaluation

On September 13, Chengyi PharmaceuticalAn announcement was released regarding the company’s drug passing the generic drug consistency evaluation. The announcement revealed that the company recently received the “Notice of Approval of Supplementary Drug Application” from the National Medical Products Administration (NMPA). The company’s dobutamine hydrochloride injection has passed the generic drug quality and efficacy consistency evaluation. The drug is available in two strengths: 2ml: 20mg and 5ml: 100mg, both of which have been approved. Dobutamine hydrochloride injection is primarily used for the short-term supportive treatment of heart failure caused by organic heart disease and post-cardiac surgery low-output syndrome. The company received the Drug Registration Approval for dobutamine hydrochloride injection (2ml:20mg) from the National Medical Products Administration (NMPA) in September 2002. In July 2024, the company submitted an application for domestic production consistency evaluation of the drug to the NMPA’s Center for Drug Evaluation, also seeking an additional 5ml:100mg strength. The ...
- Source: drugdu
- 75
- September 15, 2025
“Pharma leader ” changes! Hengrui Medicine, don’t panic

Recently, Hengrui Medicine lost its position as the “No. 1 pharmaceutical company”. In the pharmaceutical industry, BeiGene’s transcendence sends a signal. For a long time in the past, Hengrui Medicine was the undisputed leader in the pharmaceutical industry. Relying on the model of “imitation + innovation”, Hengrui has been leading the entire industry, and many of its core products once occupied half of the domestic pharmaceutical market. As early as 2021, Hengrui Medicine’s stock price continued to rise after a series of sharp increases, reaching a high of 96.7 yuan per share, and its total market value reached an astonishing 616.9 billion yuan.However, the turning point also occurred in 2021. Affected by multiple factors in the industry and the outside world, Hengrui Medicine’s growth engine gradually stalled, and the “imitation + innovation” model began to fail. In terms of performance, from 2021 to 2023, Hengrui Medicine’s revenue growth rate was ...
- Source: drugdu
- 110
- September 15, 2025
Is Sinovac Biotech’s controlling shareholder cashing out ahead of its Hong Kong IPO? Keyi Pharmaceuticals announces another 5% stake reduction plan, adding to its previous multiple reductions this year.

On September 14, Sinovac BiotechSinovac Biotech Co., Ltd. (hereinafter referred to as ” Sinovac Biotech ” or “the Company”) issued a shareholder inquiry transfer plan.The shareholder of the pre-IPO shareholder inquiry transfer (hereinafter referred to as “this inquiry transfer”) is Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as “Keyi Pharmaceutical” or “the transferor”); the total number of shares to be transferred by the transferor is 10,062,800 shares, accounting for 5.00% of the company’s total share capital; this inquiry transfer is a non-public transfer, not conducted through centralized bidding or block trading, and does not belong to a reduction in holdings through the secondary market. The transferee shall not transfer the shares acquired through the inquiry transfer within 6 months after the acquisition. It is worth noting that Keyi Pharmaceutical has recently reduced its holdings of Sinovac Biotech shares through centralized bidding and block trading.Cashing out. The company’s net ...
- Source: drugdu
- 91
- September 15, 2025
Autoimmune bispecific antibody product CS2015 selected for exhibition at the ACAAI Annual Meeting in the United States

On the morning of September 15th, CStone Pharmaceuticals (02616), a subsidiary of Zhongzheng Intelligent Finance , announced that its autoimmune and inflammatory drug candidate, CS2015 (OX40L/TSLP bispecific antibody), has been selected for presentation at the 2025 American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting will be held in Orlando, USA, from November 6th to 10th.　　CS2015 is a potential first-in-class/best-in-class bispecific antibody that simultaneously targets OX40L and TSLP. By dually inhibiting key regulators of Th2-mediated inflammatory responses, it provides a new treatment strategy for type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on drug research and development in key disease areas such as oncology, autoimmunity, and inflammation. Since its establishment, it has successfully launched four innovative drugs., and obtained approval for 16 new drug applications. The current R&D pipeline includes 16 drug ...
- Source: drugdu
- 81
- September 15, 2025
【EXPERT Q&A】What certifications are required for the export of medical devices and pharmaceutical products?

Drugdu.com expert’s response: Medical devices and pharmaceutical products require multiple certifications for export based on the requirements of target markets, covering international standards, regional regulations, and special product specifications. Below is a detailed explanation: I. International General Certifications ISO Certifications ISO 13485: An international standard for the quality management system of medical devices, serving as a foundational certification for exports. It proves that a company’s production processes comply with international norms. ISO 9001: A general quality management system certification. While not mandatory, it enhances corporate credibility. GMP Certification Good Manufacturing Practice certification ensures that production processes meet international standards, particularly for pharmaceutical-grade medical devices (e.g., vaccines, injectables). II. Regional Mandatory Certifications EU Market CE Certification: The “passport” for entering the EU market, classified by risk level: Class I low-risk products (e.g., surgical scalpels): Require a CE Declaration of Conformity. Class I*, IIa, IIb, and III high-risk products (e.g., implantable devices, pacemakers): Require ...
- Source: drugdu
- 130
- September 15, 2025
ICER Releases Cost Analysis Report on Obesity Treatments Semaglutide, Tirzepatide

The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report evaluating the comparative clinical effectiveness and value of Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) for obesity management, including their impact on other obesity-related outcomes. ICER stated that the preliminary draft represents the midpoint of its eight-month assessment process and should not be interpreted as the organization’s final conclusions.1 How Effective and Cost-Efficient are the Newest Obesity Treatments? Key Clinical Findings The initial draft found that both agents, when added to lifestyle modification, produced significant weight loss, improvements in obesity-related comorbidities, and reductions in cardiovascular risk factors. Zepbound demonstrated the greatest weight loss benefits, with average weight loss ranging from 17.8% to 20.8%, and a head-to-head trial showing 20.2% loss versus 13.7% with injectable Wegovy. Early topline results in diabetes populations also suggest promising cardiovascular benefits, including an 8% reduction in major adverse cardiovascular ...
- Source: drugdu
- 99
- September 12, 2025
FDA Releases Guidance to Promote Nonopioid Alternatives for Chronic Pain

By Stephanie Brown HealthDay ReporterWEDNESDAY, Sept. 10, 2025 (HealthDay News) — The U.S. Food and Drug Administration released draft guidance to advance safe and effective nonopioid treatment options and reduce risks tied to prescription opioid misuse. “America’s opioid crisis is not over. We must stay vigilant to address this longstanding problem in new ways. Physicians need more alternatives to opioid medications for patients suffering from chronic pain,” FDA Commissioner Marty Makary, M.D., M.P.H., said in a statement. “FDA can help by providing clear guidance like this, which makes regulatory pathways more predictable for innovators and drug developers, enabling effective, lower-risk therapies to quickly reach the millions of Americans living with chronic pain.” According to the FDA, opioids are commonly prescribed to about one in five U.S. adults living with chronic pain. This is mainly due to a lack of effective alternatives. The agency’s draft guidance underscores more efficient pathways for ...
- Source: drugdu
- 121
- September 12, 2025
Multiple favorable factors resonate, highlighting investment opportunities in the brain computer interface industry chain

Against the backdrop of strong policy support and continuous technological breakthroughs at home and abroad, the application scenarios of the brain computer interface industry have gradually become clear in recent years and have received increasing market attention. According to Wind data, the Wande Brain Computer Interface Concept Index rose by 0.32% on September 10th, indicating a clear upward trend in recent times. Among the constituent stocks of the index, Meihao Medical rose 6.98%, Kunlun Wanwei rose 4.71%, and Innovation Medical, Sino Medical, and others followed suit. Analysts believe that brain computer interface technology has become one of the strategic highlands for global technological competition. Neurorehabilitation and motor function reconstruction are expected to become the first batch of invasive brain computer interface application scenarios to move towards industrialization and commercialization. Currently, China’s brain computer interface industry is expected to usher in a golden period of development. Industry catalysis continues On September ...
- Source: drugdu
- 148
- September 12, 2025
Novo Nordisk announced plans to lay off approximately 9000 employees; Pailin Biotechnology’s controlling shareholder plans to change to China Biologics | Pharmaceutical Early Reference

Novo Nordisk announces plans to lay off approximately 9000 employees Novo Nordisk announced that the company will undergo internal restructuring and lay off approximately 9000 employees to save 8 billion Danish kroner (approximately 1.26 billion US dollars) in expenses annually. Novo Nordisk pointed out in a statement that it will carry out a comprehensive reform of the company to simplify the organizational structure, speed up decision-making, and reallocate resources to business growth opportunities in the field of diabetes and obesity. Comment: Since the beginning of this year, Novo Nordisk has lowered its performance guidance several times due to increasing sales pressure on its core product, semaglutide. This layoff plan is also an adjustment made by the company under profit pressure. NO.2 Pailin Biotechnology’s controlling shareholder plans to change to China Biology Pailin Biotechnology announced that its controlling shareholder, Gongqingcheng Shengbang Yinghao Investment Partnership Enterprise (Limited Partnership), has signed a “Share ...
- Source: drugdu
- 138
- September 12, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.